Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control

Mediators of Inflammation

Volumn 2016, Issue , 2016, Pages

  Lee, Young Sun ^a   Jun, Hee Sook ^a,b  

^a Gachon University College of Medicine   (South Korea)

^b Gil Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; ALOGLIPTIN; ANAGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; LINAGLIPTIN; LIRAGLUTIDE; LIXISENATIDE; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN; ANTIINFLAMMATORY AGENT; GLUCOSE BLOOD LEVEL;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; ATHEROSCLEROSIS; CHRONIC INFLAMMATION; CORONARY ARTERY ATHEROSCLEROSIS; DEGENERATIVE DISEASE; DIABETIC NEPHROPATHY; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; ANIMAL; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; INFLAMMATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INFLAMMATION;

EID: 84964355806     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2016/3094642     Document Type: Review

References (115)

1. C. Ørskov, L. Rabenhøj, A. Wettergren, H. Kofod, and J. J. Holst, "Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans," Diabetes, vol. 43, no. 4, pp. 535-539, 1994.
2. L. L. Kjems, J. J. Holst, A. Vølund, and S. Madsbad, "The influence of GLP-1 on glucose-stimulated insulin secretion: effects on β-cell sensitivity in type 2 and nondiabetic subjects," Diabetes, vol. 52, no. 2, pp. 380-386, 2003.
3. R. Mentlein, B. Gallwitz, and W. E. Schmidt, "Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum," European Journal of Biochemistry, vol. 214, no. 3, pp. 829-835, 1993.
4. Y.-S. Lee and H.-S. Jun, "Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells," Metabolism: Clinical and Experimental, vol. 63, no. 1, pp. 9-19, 2014.
5. M. Karaca, C. Magnan, and C. Kargar, "Functional pancreatic beta-cell mass: involvement in type 2 diabetes and therapeutic intervention," Diabetes & Metabolism, vol. 35, no. 2, pp. 77-84, 2009.
6. D. J. Drucker, "The biology of incretin hormones," Cell Metabolism, vol. 3, no. 3, pp. 153-165, 2006.
7. A. J. Tremblay, B. Lamarche, C. F. Deacon, S. J. Weisnagel, and P. Couture, "Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes," Metabolism: Clinical and Experimental, vol. 63, no. 9, pp. 1141-1148, 2014.
8. M. L. Balestrieri, M. R. Rizzo, M. Barbieri et al., "Sirtuin 6 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of incretin treatment," Diabetes, vol. 64, no. 4, pp. 1395-1406, 2015.
9. A. Varanasi, P. Patel, A. Makdissi, S. Dhindsa, A. Chaudhuri, and P. Dandona, "Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors," Endocrine Practice, vol. 18, no. 2, pp. 140-145, 2012.
10. A. J. Garber, "Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability," Diabetes Care, vol. 34, supplement 2, pp. S279-S284, 2011.
11. M. Nauck, "Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors," Diabetes, Obesity & Metabolism, vol. 18, no. 3, pp. 203-216, 2016.
12. M. Arakawa, T. Mita, K. Azuma et al., "Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4," Diabetes, vol. 59, no. 4, pp. 1030-1037, 2010.
13. B. Thorens, "Expression cloning of the pancreatic β cell receptor for the gluco- incretin hormone glucagon-like peptide 1," Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 18, pp. 8641-8645, 1992.
14. H. Fujita, T. Morii, H. Fujishima et al., "The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential," Kidney International, vol. 85, no. 3, pp. 579-589, 2014.
15. M. Romaní-Pérez, V. Outeiriño-Iglesias, M. Gil-Lozano, L. C. González-Matías, F. Mallo, and E. Vigo, "Pulmonary GLP-1 receptor increases at birth and exogenous GLP-1 receptor agonists augmented surfactant-protein levels in litters from normal and nitrofen-treated pregnant rats," Endocrinology, vol. 154, no. 3, pp. 1144-1155, 2013.
16. R. Goke, P. J. Larsen, J. D. Mikkelsen, and S. P. Sheikh, "Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites," The European Journal of Neuroscience, vol. 7, no. 11, pp. 2294-2300, 1995.
17. T. Iwai, S. Ito, K. Tanimitsu, S. Udagawa, and J.-I. Oka, "Glucagon-like peptide-1 inhibits LPS-induced IL-1β production in cultured rat astrocytes," Neuroscience Research, vol. 55, no. 4, pp. 352-360, 2006.
18. Y.-S. Lee, M.-S. Park, J.-S. Choung et al., "Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes," Diabetologia, vol. 55, no. 9, pp. 2456-2468, 2012.
19. A. D. Dobrian, Q. Ma, J. W. Lindsay et al., "Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice," The American Journal of Physiology - Endocrinology and Metabolism, vol. 300, no. 2, pp. E410-E421, 2011.
20. C. Cabou and R. Burcelin, "GLP-1, the gut-brain, and brain-periphery axes," Review of Diabetic Studies, vol. 8, no. 3, pp. 418-431, 2011.
21. X.-C. Wang, A. M. Gusdon, H. Liu, and S. Qu, "Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation," World Journal of Gastroenterology, vol. 20, no. 40, pp. 14821-14830, 2014.
22. M. Blandino-Rosano, G. Perez-Arana, J. M. Mellado-Gil, C. Segundo, and M. Aguilar-Diosdado, "Anti-proliferative effect of pro-inflammatory cytokines in cultured β cells is associated with extracellular signal-regulated kinase 1/2 pathway inhibition: protective role of glucagon-like peptide -1," Journal of Molecular Endocrinology, vol. 41, no. 1-2, pp. 35-44, 2008.
23. H. Liu, A. E. Dear, L. B. Knudsen, and R. W. Simpson, "A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules," The Journal of Endocrinology, vol. 201, no. 1, pp. 59-66, 2009.
24. V. Parthsarathy and C. Hölscher, "The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain," European Journal of Pharmacology, vol. 700, no. 1-3, pp. 42-50, 2013.
25. C. Marques, C. Mega, A. Gonçalves et al., "Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals," Mediators of Inflammation, vol. 2014, Article ID 538737, 15 pages, 2014.
26. -/- mice," Diabetologia, vol. 55, no. 8, pp. 2267-2275, 2012.
27. M. Vila, V. Jackson-Lewis, C. Guégan et al., "The role of glial cells in Parkinson's disease," Current Opinion in Neurology, vol. 14, no. 4, pp. 483-489, 2001.
28. N. Ao, J. Yang, X. Wang, and J. Du, "Glucagon-like peptide-1 preserves non-alcoholic fatty liver disease through inhibition of the endoplasmic reticulum stress-associated pathway," Hepatology Research, 2015.
29. R. O. Crajoinas, F. T. Oricchio, T. D. Pessoa et al., "Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1," The American Journal of Physiology-Renal Physiology, vol. 301, no. 2, pp. F355-F363, 2011.
30. S. Gou, T. Zhu, W. Wang, M. Xiao, X.-C. Wang, and Z.-H. Chen, "Glucagon like peptide-1 attenuates bleomycin-induced pulmonary fibrosis, involving the inactivation of NF-κB in mice," International Immunopharmacology, vol. 22, no. 2, pp. 498-504, 2014.
31. A. E. Hogan, A. M. Tobin, T. Ahern et al., "Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis," Diabetologia, vol. 54, no. 11, pp. 2745-2754, 2011.
32. M. Dorecka, K. Siemianowicz, T. Francuz et al., "Exendin-4 and GLP-1 decreases induced expression of ICAM-1, VCAM-1 and RAGE in human retinal pigment epithelial cells," Pharmacological Reports, vol. 65, no. 4, pp. 884-890, 2013.
33. J.-W. Yoon and H.-S. Jun, "Autoimmune destruction of pancreatic β cells," American Journal of Therapeutics, vol. 12, no. 6, pp. 580-591, 2005.
34. C. R. Kahn, "Banting lecture: insulin action, diabetogenes, and the cause of type II diabetes," Diabetes, vol. 43, no. 8, pp. 1066-1084, 1994.
35. G. M. Reaven, "Banting lecture 1988. Role of insulin resistance in human disease," Diabetes, vol. 37, no. 12, pp. 1595-1607, 1988.
36. S. I. Taylor, D. Accili, and Y. Imai, "Insulin resistance or insulin deficiency. Which is the primary cause of NIDDM?" Diabetes, vol. 43, no. 6, pp. 735-740, 1994.
37. S. Cernea and M. Dobreanu, "Diabetes and beta cell function: from mechanisms to evaluation and clinical implications," Biochemia Medica, vol. 23, no. 3, pp. 266-280, 2013.
38. P. A. Halban, K. S. Polonsky, D. W. Bowden et al., "β-Cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment," Diabetes Care, vol. 37, no. 6, pp. 1751-1758, 2014.
39. M. Cnop, N. Welsh, J.-C. Jonas, A. Jörns, S. Lenzen, and D. L. Eizirik, "Mechanisms of pancreatic β-cell death in type 1 and type 2 diabetes: many differences, few similarities," Diabetes, vol. 54, supplement 2, pp. S97-S107, 2005.
40. I. L. Campbell, A. Iscaro, and L. C. Harrison, "IFN-γ and tumor necrosis factor-α: cytotoxicity to murine islets of Langerhans," Journal of Immunology, vol. 141, no. 7, pp. 2325-2329, 1988.
41. C. Park, J.-R. Kim, J.-K. Shim et al., "Inhibitory effects of streptozotocin, tumor necrosis factor-α, and interleukin-1β on glucokinase activity in pancreatic islets and gene expression of GLUT2 and glucokinase," Archives of Biochemistry and Biophysics, vol. 362, no. 2, pp. 217-224, 1999.
42. M. Y. Donath, J. A. Ehses, K. Maedler et al., "Mechanisms of β-cell death in type 2 diabetes," Diabetes, vol. 54, supplement 2, pp. S108-S113, 2005.
43. C. Huang, L. Yuan, and S. Cao, "Endogenous GLP-1 as a key self-defense molecule against lipotoxicity in pancreatic islets," International Journal of Molecular Medicine, vol. 36, no. 1, pp. 173-185, 2015.
44. K. Velmurugan, A. N. Balamurugan, G. Loganathan, A. Ahmad, B. J. Hering, and S. Pugazhenthi, "Antiapoptotic actions of exendin-4 against hypoxia and cytokines are augmented by CREB," Endocrinology, vol. 153, no. 3, pp. 1116-1128, 2012.
45. L. Tian, J. Gao, J. Hao et al., "Reversal of new-onset diabetes through modulating inflammation and stimulating β-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor," Endocrinology, vol. 151, no. 7, pp. 3049-3060, 2010.
46. A. S. Akarte, B. P. Srinivasan, S. Gandhi, and S. Sole, "Chronic DPP-IV inhibition with PKF-275-055 attenuates inflammation and improves gene expressions responsible for insulin secretion in streptozotocin induced diabetic rats," European Journal of Pharmaceutical Sciences, vol. 47, no. 2, pp. 456-463, 2012.
47. Y. Zhang, Y. Chen, J. Cheng, Z. Guo, Y. Lu, and B. Tian, "DPP IV inhibitor suppresses STZ-induced islets injury dependent on activation of the IGFR/Akt/mTOR signaling pathways by GLP-1 in monkeys," Biochemical and Biophysical Research Communications, vol. 456, no. 1, pp. 139-144, 2015.
48. U. Pugazhenthi, K. Velmurugan, A. Tran, G. Mahaffey, and S. Pugazhenthi, "Anti-inflammatory action of exendin-4 in human islets is enhanced by phosphodiesterase inhibitors: potential therapeutic benefits in diabetic patients," Diabetologia, vol. 53, no. 11, pp. 2357-2368, 2010.
49. S. R. Cechin, I. Pérez-Álvarez, E. Fenjves et al., "Anti-inflammatory properties of exenatide in human pancreatic islets," Cell Transplantation, vol. 21, no. 4, pp. 633-648, 2012.
50. H. Kanda, S. Tateya, Y. Tamori et al., "MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity,"The Journal of Clinical Investigation, vol. 116, no. 6, pp. 1494-1505, 2006.
51. S. P. Weisberg, D. Hunter, R. Huber et al., "CCR2 modulates inflammatory and metabolic effects of high-fat feeding," Journal of Clinical Investigation, vol. 116, no. 1, pp. 115-124, 2006.
52. S. Winer, Y. Chan, G. Paltser et al., "Normalization of obesity-associated insulin resistance through immunotherapy," Nature Medicine, vol. 15, no. 8, pp. 921-929, 2009.
53. T. M. Jensen, K. Saha, and W. M. Steinberg, "Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials," Diabetes Care, vol. 38, pp. 1058-1066, 2015.
54. A. S. Franks, P. H. Lee, and C. M. George, "Pancreatitis: a potential complication of liraglutide?" Annals of Pharmacotherapy, vol. 46, no. 11, pp. 1547-1553, 2012.
55. P. C. Butler, M. Elashoff, R. Elashoff, and E. A. M. Gale, "A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe?" Diabetes Care, vol. 36, no. 7, pp. 2118-2125, 2013.
56. P. J. Pussinen, K. Tuomisto, P. Jousilahti, A. S. Havulinna, J. Sundvall, and V. Salomaa, "Endotoxemia, immune response to periodontal pathogens, and systemic inflammation associate with incident cardiovascular disease events," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 6, pp. 1433-1439, 2007.
57. C. J. Kelly, S. P. Colgan, and D. N. Frank, "Of microbes and meals: the health consequences of dietary endotoxemia," Nutrition in Clinical Practice, vol. 27, no. 2, pp. 215-225, 2012.
58. J. Frostegård, "Immunity, atherosclerosis and cardiovascular disease," BMC Medicine, vol. 11, article 117, 2013.
59. K. C. Dozier, E. L. Cureton, R. O. Kwan, B. Curran, J. Sadjadi, and G. P. Victorino, "Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation," Peptides, vol. 30, no. 9, pp. 1735-1741, 2009.
60. N. M. Krasner, Y. Ido, N. B. Ruderman, and J. M. Cacicedo, "Glucagon-Like Peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism," PLoS ONE, vol. 9, no. 5, Article ID e97554, 2014.
61. Y. Hattori, T. Jojima, A. Tomizawa et al., "A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells," Diabetologia, vol. 53, no. 10, pp. 2256-2263, 2010.
62. A. Shiraki, J.-I. Oyama, H. Komoda et al., "The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells," Atherosclerosis, vol. 221, no. 2, pp. 375-382, 2012.
63. Y. Wang, E. T. Parlevliet, J. J. Geerling et al., "Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration," British Journal of Pharmacology, vol. 171, no. 3, pp. 723-734, 2014.
64. Y. Dai, D. Dai, X. Wang, Z. Ding, and J. L. Mehta, "DPP-4 inhibitors repress NLRP3 inflammasome and interleukin-1beta via GLP-1 receptor in macrophages through protein kinase C pathway," Cardiovascular Drugs and Therapy, vol. 28, no. 5, pp. 425-432, 2014.
65. H. M. Salim, D. Fukuda, Y. Higashikuni et al., "Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice," Vascular Pharmacology, vol. 79, pp. 16-23, 2015.
66. Y. Zeng, C. Li, M. Guan et al., "The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms," Cardiovascular Diabetology, vol. 13, article 32, 2014.
67. S. Tang, Q. Zhang, H. Tang et al., "Effects of glucagon-like peptide-1 on advanced glycation endproduct-induced aortic endothelial dysfunction in streptozotocin-induced diabetic rats: possible roles of Rho kinase- and AMP kinase-mediated nuclear factor κB signaling pathways," Endocrine, pp. 1-10, 2016.
68. J. Matsubara, S. Sugiyama, K. Sugamura et al., "A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice," Journal of the American College of Cardiology, vol. 59, no. 3, pp. 265-276, 2012.
69. K. Akita, K. Isoda, K. Shimada, and H. Daida, "Dipeptidylpeptidase-4 inhibitor, alogliptin, attenuates arterial inflammation and neointimal formation after injury in low-density lipoprotein (LDL) receptor-deficient mice," Journal of the American Heart Association, vol. 4, no. 3, Article ID e001469, 2015.
70. -/- mice," Atherosclerosis, vol. 231, no. 2, pp. 427-435, 2013.
71. M. Lappas, "Anti-inflammatory properties of sirtuin 6 in human umbilical vein endothelial cells,"Mediators of Inflammation, vol. 2012,Article ID597514, 11 pages, 2012.
72. X. Du, X. Hu, and J. Wei, "Anti-inflammatory effect of exendin-4 postconditioning during myocardial ischemia and reperfusion," Molecular Biology Reports, vol. 41, no. 6, pp. 3853-3857, 2014.
73. Y. Cai, X. Hu, B. Yi, T. Zhang, and Z. Wen, "Glucagon-like peptide-1 receptor agonist protects against hyperglycemia-induced cardiocytes injury by inhibiting high mobility group box 1 expression," Molecular Biology Reports, vol. 39, no. 12, pp. 10705-10711, 2012.
74. Y.-S. Liu, Z.-W. Huang, L. Wang et al., "Sitagliptin alleviated myocardial remodeling of the left ventricle and improved cardiac diastolic dysfunction in diabetic rats," Journal of Pharmacological Sciences, vol. 127, no. 3, pp. 260-274, 2015.
75. M. L. Block and J.-S. Hong, "Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism," Progress in Neurobiology, vol. 76, no. 2, pp. 77-98, 2005.
76. E. G. McGeer and P. L. McGeer, "The role of anti-inflammatory agents in Parkinson's disease," CNS Drugs, vol. 21, no. 10, pp. 789-797, 2007.
77. R. E. Mrak and W. S. T. Griffin, "Glia and their cytokines in progression of neurodegeneration," Neurobiology of Aging, vol. 26, no. 3, pp. 349-354, 2005.
78. E. M. C. Schrijvers, J. C. M. Witteman, E. J. G. Sijbrands, A. Hofman, P. J. Koudstaal, and M. M. B. Breteler, "Insulin metabolism and the risk of Alzheimer disease: the Rotterdam Study," Neurology, vol. 75, no. 22, pp. 1982-1987, 2010.
79. C. Kappe, L. M. Tracy, C. Patrone, K. Iverfeldt, and Å. Sjöholm, "GLP-1 secretion by microglial cells and decreased CNS expression in obesity," Journal of Neuroinflammation, vol. 9, article 276, 2012.
80. T. Perry and N. H. Greig, "Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease," Current Alzheimer Research, vol. 2, no. 3, pp. 377-385, 2005.
81. C. Holscher, "Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease," Recent Patents on CNS Drug Discovery, vol. 5, no. 2, pp. 109-117, 2010.
82. A. Harkavyi and P. S. Whitton, "Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection," British Journal of Pharmacology, vol. 159, no. 3, pp. 495-501, 2010.
83. A. Hamilton and C. Hölscher, "Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system," NeuroReport, vol. 20, no. 13, pp. 1161-1166, 2009.
84. A. Hamilton, S. Patterson, D. Porter, V. A. Gault, and C. Holscher, "Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain," Journal of Neuroscience Research, vol. 89, no. 4, pp. 481-489, 2011.
85. K. Hunter and C. Hölscher, "Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis," BMC Neuroscience, vol. 13, article 33, 2012.
86. P. L. Mcclean, V. Parthsarathy, E. Faivre, and C. Holscher, "The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease," The Journal of Neuroscience, vol. 31, no. 17, pp. 6587-6594, 2011.
87. N. Gong, Q. Xiao, B. Zhu et al., "Activation of spinal glucagon-like peptide-1 receptors specifically suppresses pain hypersensitivity," Journal of Neuroscience, vol. 34, no. 15, pp. 5322-5334, 2014.
88. K. Plaschke and S. Hoyer, "Action of the diabetogenic drug streptozotocin on glycolytic and glycogenolytic metabolism in adult rat brain cortex and hippocampus," International Journal of Developmental Neuroscience, vol. 11, no. 4, pp. 477-483, 1993.
89. V. Solmaz, B. P. C¸inar, G. Yiǧittürk, T. C¸avus¸oǧlu, D. Tas¸kiran, and O. Erbas¸, "Exenatide reduces TNF-α expression and improves hippocampal neuron numbers and memory in streptozotocin treated rats," European Journal of Pharmacology, vol. 765, pp. 482-487, 2015.
90. T. Iwai, T. Sawabe, K. Tanimitsu, M. Suzuki, S. Sasaki-Hamada, and J.-I. Oka, "Glucagon-like peptide-1 protects synaptic and learning functions from neuroinflammation in rodents," Journal of Neuroscience Research, vol. 92, no. 4, pp. 446-454, 2014.
91. P. L. McClean and C. Hölscher, "Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease," Neuropharmacology, vol. 76, pp. 57-67, 2014.
92. C. Hölscher, "The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease," Alzheimer's & Dementia, vol. 10, no. 1, pp. S47-S54, 2014.
93. M. D'Amico, C. Di Filippo, R. Marfella et al., "Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice," Experimental Gerontology, vol. 45, no. 3, pp. 202-207, 2010.
94. S. Kim, M. Moon, and S. Park, "Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease," The Journal of Endocrinology, vol. 202, no. 3, pp. 431-439, 2009.
95. J. Lee, S.-W. Hong, S. W. Chae et al., "Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice," PLoS ONE, vol. 7, no. 2, Article ID e31394, 2012.
96. F. Xu, Z. Li, X. Zheng et al., "SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis," Diabetes, vol. 63, no. 11, pp. 3637-3646, 2014.
97. Y. Eguchi, Y. Kitajima, H. Hyogo et al., "Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J)," Hepatology Research, vol. 45, no. 3, pp. 269-278, 2015.
98. G. Derosa, I. G. Franzetti, F. Querci et al., "Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes," Diabetic Medicine, vol. 29, no. 12, pp. 1515-1523, 2012.
99. M. Saraheimo, A.-M. Teppo, C. Forsblom, J. Fagerudd, and P.- H. Groop, "Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients," Diabetologia, vol. 46, no. 10, pp. 1402-1407, 2003.
100. C. D. A. Stehouwer, M.-A. Gall, J. W. R. Twisk, E. Knudsen, J. J. Emeis, and H.-H. Parving, "Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death," Diabetes, vol. 51, no. 4, pp. 1157-1165, 2002.
101. R. Kodera, K. Shikata, H. U. Kataoka et al., "Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes," Diabetologia, vol. 54, no. 4, pp. 965-978, 2011.
102. P. Schlatter, C. Beglinger, J. Drewe, and H. Gutmann, "Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells," Regulatory Peptides, vol. 141, no. 1-3, pp. 120-128, 2007.
103. S. Sancar-Bas, S. Gezginci-Oktayoglu, and S. Bolkent, "Exendin-4 attenuates renal tubular injury by decreasing oxidative stress and inflammation in streptozotocin-induced diabetic mice," Growth Factors, vol. 33, no. 5-6, pp. 419-429, 2015.
104. M. Gangadharan Komala, S. Gross, A. Zaky, C. Pollock, and U. Panchapakesan, "Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes," Nephrology, 2015.
105. R. Kodera, K. Shikata, T. Takatsuka et al., "Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes," Biochemical and Biophysical Research Communications, vol. 443, no. 3, pp. 828-833, 2014.
106. S. Nakashima, T. Matsui, M. Takeuchi, and S.-I. Yamagishi, "Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis," Hormone and Metabolic Research, vol. 46, no. 10, pp. 717-721, 2014.
107. Y. Higashijima, T. Tanaka, J. Yamaguchi, S. Tanaka, and M. Nangaku, "Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury," The American Journal of Physiology - Renal Physiology, vol. 308, no. 8, pp. F878-F887, 2015.
108. D. Katagiri, Y. Hamasaki, K. Doi et al., "Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection," Journal of the American Society of Nephrology, vol. 24, no. 12, pp. 2034-2043, 2013.
109. Y.-T. Chen, T.-H. Tsai, C.-C. Yang et al., "Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction," Journal of Translational Medicine, vol. 11, article 270, 2013.
110. T. Zhu, X.-L. Wu, W. Zhang, and M. Xiao, "Glucagon like peptide-1 (GLP-1) modulates OVA-induced airway inflammation and mucus secretion involving a protein kinase A (PKA)-dependent nuclear factor-κB (NF-κB) signaling pathway in mice," International Journal of Molecular Sciences, vol. 16, no. 9, pp. 20195-20211, 2015.
111. E. Zhang, F. Xu, H. Liang et al., "GLP-1 receptor agonist exenatide attenuates the detrimental effects of obesity on inflammatory profile in testis and sperm quality in mice," American Journal of Reproductive Immunology, vol. 74, no. 5, pp. 457-466, 2015.
112. H. W. Bakos, R. C. Henshaw, M. Mitchell, and M. Lane, "Paternal body mass index is associated with decreased blastocyst development and reduced live birth rates following assisted reproductive technology," Fertility and Sterility, vol. 95, no. 5, pp. 1700-1704, 2011.
113. D. J. Drucker and C. F. Rosen, "Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology," Diabetologia, vol. 54, no. 11, pp. 2741-2744, 2011.
114. A. Faurschou, F. K. Knop, J. P. Thyssen, C. Zachariae, L. Skov, and T. Vilsbøll, "Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide," Acta Diabetologica, vol. 51, no. 1, pp. 147-150, 2014.
115. S. Steven, M. Hausding, S. Kröller-Schön et al., "Gliptin and GLP-1 analog treatment improves survival and vascular inflammation/dysfunction in animals with lipopolysaccharide-induced endotoxemia," Basic Research in Cardiology, vol. 110, no. 2, article 6, 2015.